image
Healthcare - Biotechnology - NASDAQ - US
$ 71.38
0.197 %
$ 7.57 B
Market Cap
62.07
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one CORT stock under the worst case scenario is HIDDEN Compared to the current market price of 71.4 USD, Corcept Therapeutics Incorporated is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one CORT stock under the base case scenario is HIDDEN Compared to the current market price of 71.4 USD, Corcept Therapeutics Incorporated is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one CORT stock under the best case scenario is HIDDEN Compared to the current market price of 71.4 USD, Corcept Therapeutics Incorporated is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CORT

image
$120.0$120.0$110.0$110.0$100.0$100.0$90.0$90.0$80.0$80.0$70.0$70.0$60.0$60.0$50.0$50.0$40.0$40.0Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
675 M REVENUE
39.94%
137 M OPERATING INCOME
27.66%
141 M NET INCOME
33.04%
198 M OPERATING CASH FLOW
55.91%
-178 M INVESTING CASH FLOW
-195.37%
-28.3 M FINANCING CASH FLOW
80.94%
157 M REVENUE
-13.57%
3.42 M OPERATING INCOME
-86.48%
20.5 M NET INCOME
-32.39%
5.13 M OPERATING CASH FLOW
-91.35%
-3.17 M INVESTING CASH FLOW
95.07%
-39.8 M FINANCING CASH FLOW
-772.11%
Balance Sheet Corcept Therapeutics Incorporated
image
Current Assets 472 M
Cash & Short-Term Investments 383 M
Receivables 54 M
Other Current Assets 34.3 M
Non-Current Assets 369 M
Long-Term Investments 220 M
PP&E 8.01 M
Other Non-Current Assets 141 M
45.60 %6.42 %4.08 %26.15 %16.79 %Total Assets$840.6m
Current Liabilities 141 M
Accounts Payable 15.4 M
Short-Term Debt 829 K
Other Current Liabilities 125 M
Non-Current Liabilities 20.2 M
Long-Term Debt 0
Other Non-Current Liabilities 20.2 M
9.55 %77.39 %12.54 %Total Liabilities$161.0m
EFFICIENCY
Earnings Waterfall Corcept Therapeutics Incorporated
image
Revenue 675 M
Cost Of Revenue 10.9 M
Gross Profit 664 M
Operating Expenses 527 M
Operating Income 137 M
Other Expenses -4.26 M
Net Income 141 M
700m700m600m600m500m500m400m400m300m300m200m200m100m100m00675m(11m)664m(527m)137m4m141mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
98.39% GROSS MARGIN
98.39%
20.29% OPERATING MARGIN
20.29%
20.70% NET MARGIN
20.70%
20.56% ROE
20.56%
16.62% ROA
16.62%
17.09% ROIC
17.09%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Corcept Therapeutics Incorporated
image
200m200m180m180m160m160m140m140m120m120m100m100m80m80m60m60m40m40m20m20m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 141 M
Depreciation & Amortization 1.34 M
Capital Expenditures -2.17 M
Stock-Based Compensation 61.4 M
Change in Working Capital 45.3 M
Others 35.2 M
Free Cash Flow 196 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Corcept Therapeutics Incorporated
image
Wall Street analysts predict an average 1-year price target for CORT of $85.3 , with forecasts ranging from a low of $38 to a high of $145 .
CORT Lowest Price Target Wall Street Target
38 USD -46.76%
CORT Average Price Target Wall Street Target
85.3 USD 19.48%
CORT Highest Price Target Wall Street Target
145 USD 103.14%
Price
Max Price Target
Min Price Target
Average Price Target
1601601401401201201001008080606040402020Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 17
6. Ownership
Insider Ownership Corcept Therapeutics Incorporated
image
Sold
0-3 MONTHS
19 M USD 7
3-6 MONTHS
40.6 M USD 6
6-9 MONTHS
1.63 M USD 4
9-12 MONTHS
1.77 M USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Corcept: Remains A Strong Buy On Recent Weakness And Aggressive Sales Force Hiring Corcept Therapeutics remains a strong buy, with recent stock weakness attributed to put options trading rather than fundamental issues. Management maintains aggressive 2025 and long-term revenue guidance, supported by increased testing, salesforce expansion, and a backlog of prescriptions. The company is submitting a New Drug Application for Relacorilant in ovarian cancer, opening a new oncology revenue stream beyond endocrinology. seekingalpha.com - 2 weeks ago
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, presented results from its DAZALS study of dazucorilant in patients with ALS at the European Network to Cure ALS (ENCALS) 2025 annual meeting. The presentation can be found here. DAZALS is a randomi. businesswire.com - 3 weeks ago
Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer in a late-breaking oral presentation at the ASCO 2025. businesswire.com - 1 month ago
New Strong Sell Stocks for May 29th CORT, AETUF and MITT have been added to the Zacks Rank #5 (Strong Sell) List on May 29, 2025. zacks.com - 1 month ago
CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall Corcept's first-quarter 2025 earnings meet estimates while revenues miss the same. The company reiterates its revenue guidance for 2025. zacks.com - 1 month ago
Corcept Therapeutics Incorporated (CORT) Q1 2025 Earnings Call Transcript Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q1 2025 Earnings Conference Call May 5, 2025 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Sean Maduck - President, Endocrinology Charlie Robb - Chief Business Officer Joe Belanoff - Chief Executive Officer Roberto Vieira - President, Oncology Bill Guyer - Chief Development Officer Conference Call Participants Edward Nash - Canaccord David Amsellem - Piper Sandler Joon Lee - Truist Securities RK - H. C. Wainwright Operator Thank you for standing by. seekingalpha.com - 1 month ago
Corcept Therapeutics (CORT) Meets Q1 Earnings Estimates Corcept Therapeutics (CORT) came out with quarterly earnings of $0.17 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.25 per share a year ago. zacks.com - 1 month ago
CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 5, 2025. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN. businesswire.com - 2 months ago
CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025 REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, will present data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the 2025 American Society of Clinical Oncology (ASC. businesswire.com - 2 months ago
Corcept: Maintaining Strong Buy Even After 4Q Revenue And Earnings Miss Despite a Q4 revenue miss, Corcept's 2025 revenue still grew 40% to $675 million, and management provided strong guidance for 2025 and beyond, projecting up to $5 billion in revenue. Corcept's potential patient population has expanded significantly from 10,000 to over 1 million in the past year, and has promising drugs in the pipeline, making it a strong acquisition target. The company announced positive trial results for an ovarian cancer medication, opening an entirely new revenue stream. seekingalpha.com - 2 months ago
Diabetes Care Publishes Results From Prevalence Phase Of Corcept's CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the publication of findings from the prevalence phase of the CATALYST trial in Diabetes Care, a peer-reviewed journal published by the American Diabetes Association. The publication,. businesswire.com - 2 months ago
It's Still Early For Corcept: With Multiple Growth Opportunities Ahead, It's No Longer Just A One Drug Wonder Corcept is transitioning from a single-product company to a multi-product, multi-market Platform Growth™ company, promising rapid revenue and earnings growth. Relacorilant's success in platinum-resistant ovarian cancer and potential FDA approval for hypercortisolism could significantly boost Corcept's market presence and revenue. Corcept's expanding pipeline includes promising treatments for prostate cancer, ALS, MASH, and resistant hypertension, diversifying its product portfolio and reducing investor risk. seekingalpha.com - 2 months ago
8. Profile Summary

Corcept Therapeutics Incorporated CORT

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 7.57 B
Dividend Yield 0.00%
Description Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
Contact 149 Commonwealth Drive, Menlo Park, CA, 94025 https://www.corcept.com
IPO Date April 14, 2004
Employees 500
Officers Dr. William Guyer Pharm.D. Chief Development Officer Dr. Hazel Hunt Ph.D. Chief Scientific Officer Mr. Joseph Douglas Lyon Chief Accounting & Technology Officer Dr. Joseph K. Belanoff M.D. Co-Founder, President, Chief Executive Officer & Director Mr. Atabak Mokari Chief Financial Officer & Treasurer Ms. Amy Flood Chief Human Resources & Communications Officer Mr. Sean Maduck President of Endocrinology Mr. Roberto W. Vieira President of Oncology Ms. Monica Tellado President of Emerging Markets Mr. Gary Charles Robb J.D. Chief Business Officer & Secretary